Please assess the completion status of the following clinical trial:

Trial Title: Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female age 18 to 75 years.~2. Presence of newly formed gallstones (size up to 6 mm) with or without sludge diagnosed by ultrasound within 3 or 6 months after bariatric surgery following normal ultrasound.~3. Bariatric surgery conducted during the last 12 months~4. Patients with sleeve gastrectomy or laparoscopic banding of the upper stomach will be included.~5. Signature of the written informed consent.~6. Negative pregnancy test at study entry for females of child bearing potential.~7. Females of child bearing potential practicing reliable contraception throughout the study period (not including oral contraceptives).~8. Hypertensive patients must be well controlled by stable dose of anti-hypertensive medication for at least 2 months prior to screening (and the stable dose can be maintained throughout the study).~9. Patients treated with vitamin E(\>400IU/die), or Polyunsaturated fatty acid (\>2g/d) or Ursodeoxycholic acid or fish oil can be included if drugs are stopped at least 3 months prior to study enrollment to the study and up to it end.~10. For patients with type 2 Diabetes, glycaemia must be controlled (Glycosylated Hemoglobin A1C ≤ 8% while any HbA1C increment should not exceed 1% during 6 month prior to enrollment). If glycaemia is controlled by medications, qualitative change is not permitted within 3 months prior to randomization and should be avoided during the study. Treatments with Metformin, Sulfamides and Insulin are authorized. Sulfamides and insulin are permitted if glycaemia is self-monitored by the patient.~Exclusion Criteria:~1. Patients with ultrasonography evidence of gallstones in gallbladder before having the bariatric surgery.~2. Patients with no clear ultrasonography evidence of gallstones -free gallbladder during the year prior their bariatric surgery.~3. Patients with ultrasonography evidence of gallstones more than 1 year following bariatric surgery.~4. Patients with ultrasonography evidence of gallstones in size greater than 9 mm less than 1 year following bariatric surgery.~5. Weight \>140 Kg or BMI \>40~6. Known alcohol and/or any other drug abuse or dependence in the last five years~7. Known history or presence of clinically significant cardiovascular, hepatic, gastrointestinal, neurologic, pulmonary, endocrine, psychiatric, neoplastic disorder or nephritic syndrome.~8. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs including bile salt metabolism (e.g. inflammatory bowel disease (IDB); previous intestinal (ileal or colonic) operation; chronic pancreatic; celiac disease or previous vagotomy~9. Uncontrolled blood pressure~10. Patients with HIV~11. Patients with renal dysfunction eGFR\< 60.~12. Patients with pancreatitis, cholangitis or cholecystitis in the previous 4 months.~13. Women who are pregnant or breastfeeding~14. Type 1 Diabetes.~15. .Metformin, Fibrates, Statins, Insulin, Sulfonilurea not provided on a stable dose in the last 6 months.~16. Patients who are treated with Valproic acid, Tamoxifen, Methotreksate, Amiodaron.~17. Treatment with Rifaximin.~18. Homeopathic and/or Alternative treatments. Any treatment should be stopped before the screening period.~19. Serum creatine phosphokinase (CPK), ALT, AST and/or alkaline phosphatase \>3X the upper limit of normal (ULN). Patients with an intermittent CPK elevation may have the repeated measurement prior to randomization; a CPK retest \> 3X ULN leads to exclusion.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Aramchol 400 mg (Type: EXPERIMENTAL): • One tablet of Aramchol 400 mg and one tablet of Placebo
- Aramchol 600 mg (Type: EXPERIMENTAL): • One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
- Placebo (Type: PLACEBO_COMPARATOR): • Two tablet of Aramchol matching placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility